Dosen af ViraferonPeg i monoterapi bør reduceres hos patienter med moderat eller kraftigt nedsat nyrefunktion (se pkt. ###>113 ViraferonPeg for monotherapy should be reduced in patients with moderate or severe renal impairment (see sections 4.2 and 4.4).